Sanofi SA (ADR)'s (SNY) stock price took a hit in yesterday's trading session as investors expressed disapproval over the decision by the company's board of directors to oust the now ex-CEO Chris Viehbacher from his position.
Sanofi SA (ADR) (SNY) will report financial and operational results for the third quarter of its 2014 fiscal year (3QFY14) on Tuesday, October 28 before the opening bell at the Euronext Paris stock exchange.
The stalled effort of Sanofi SA (ADR) (NYSE:SNY) to sell its $8 billion drug portfolio happens to be the latest example of how the company's Chief Executive Officer Chris Viehbacher is functioning even without informing the board members.
Sanofi SA (ADR) (NYSE:SNY) vaccines separation, Sanofi Pasteur, declared the starting of a phase III clinical trial in India for its trial rotavirus vaccine, developed and making by its associate Shantha Biotechnics in Hyderabad, India.
Sanofi SA (ADR) (SNY) responded to allegations of bribery activity in the Middle East and Africa late Monday, stating that it has notified relevant US authorities about the issue and is conducting a private investigation into the matter.
Manhattan, NY- Thursday, October 30, 2014 - (Techsonian) �Sanofi SA (ADR) (NYSE:SNY) reported that detailed positive results from four Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia.
(ADR) (FUJIY) to step forward with their respective anti-Ebola treatment therapies. The Ebola outbreak has claimed about 3,500 lives as of October 8. This might have brought out the pharmaceutical industry's human side.